Drug Trial Radar · NCT02557789
Bioavailability and Pharmacokinetics of Lefamulin When Administered to Fed and Fasted Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Sep 23, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Jun 2015
Primary completion
Jun 2015
Study completion Jun 2015
Sponsor
- Lead sponsor
- Nabriva Therapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Sep 23, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1 study to assess the bioavailability and pharmacokinetics of a 600 mg immediate release tablet formulation of lefamulin when administered to fed and fasted healthy subjects in comparison to an intravenous formulation and a capsule formulation.
Conditions
- Healthy
Interventions
LefamulinDrug
Lefamulin administered iv or orally in the fasted state and orally in the fed state
Primary outcomes
What the sponsor says the trial is designed to measure.
- The area under the concentration time curve (AUC) of an intravenous and oral formulation of lefamulin in the fasting stateTime frame: 36 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Clinical
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.